QuarterlyIQ Insights · MRNA
Price
Price, valuation, and the composite score on the same time axis. Scroll over the price chart to zoom.
Price
Daily closes. Earnings/event dots inline.
What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $47.73. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
By method
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Conf. |
|---|---|---|---|---|---|---|
| Peer EV/Sales | 12M | $166.44 | 15.1 | 10.82 | TTM | 37 |
| Peer P/S | 12M | $37.26 | 3.4 | 10.82 | TTM | 37 |
| Peer EV/Sales | 3Y | $62.01 | 15.1 | 3.90 | Analyst | 36 |
| Peer P/S | 3Y | $13.42 | 3.4 | 3.90 | Analyst | 36 |
| Peer EV/Sales | 5Y | $32.98 | 15.1 | 1.97 | Analyst | 34 |
| Peer P/S | 5Y | $6.80 | 3.4 | 1.97 | Analyst | 34 |
Composite score history
Daily snapshots of the composite. Zero is the dotted line. Above it leans positive.
P/E history
Monthly trailing P/E with quartile reference lines.
Composite score history currently shows a rolling 60-day window. We're extending it back through full coverage and adding a “consensus-then vs. actual-now” overlay (what our valuation estimate said on a past date versus where the price actually landed).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.